Barriers and facilitators of exploiting the potential of value-added medicines.
| Autor: | Petykó ZI; Center for Health Technology Assessment, Semmelweis University , Budapest, Hungary.; Syreon Research Institute , Budapest, Hungary., Inotai A; Center for Health Technology Assessment, Semmelweis University , Budapest, Hungary.; Syreon Research Institute , Budapest, Hungary., Holtorf AP; Health Outcomes Strategies , Basel, Switzerland., Brixner D; Pharmacotherapy Outcomes Research Center, Department of Pharmacotherapy, University of Utah , Salt Lake City, UT, USA., Kaló Z; Center for Health Technology Assessment, Semmelweis University , Budapest, Hungary.; Syreon Research Institute , Budapest, Hungary. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Expert review of pharmacoeconomics & outcomes research [Expert Rev Pharmacoecon Outcomes Res] 2020 Jun; Vol. 20 (3), pp. 229-236. Date of Electronic Publication: 2020 Apr 29. |
| DOI: | 10.1080/14737167.2020.1758558 |
| Abstrakt: | Introduction: Pharmaceutical research and development (R&D) is costly and only a minority of patients can access innovative medicines due to affordability constraints. Value-added medicines (VAMs) can offer potential benefits at significantly lower R&D costs. Areas Covered: VAMs may address different health care needs and problems, including off-label use of medicines, poor patient adherence, problems related to polypharmacy, need for home and/or personalized health care services. However, several barriers prevent societies from maximizing the benefits of incremental innovation related to VAMs. Generic manufacturers have limited budget and experience to demonstrate the value of new VAMs. Current market exclusivity options do not efficiently exclude freeridership and do not guarantee a return on investment for VAM innovators. Value propositions of VAMs are limitedly consistent with current HTA frameworks, consequently, incremental innovation is not acknowledged, nor rewarded with differential pricing by payers. Moreover, VAMs are often perceived solely as generic medicines by prescribers. Expert Opinion: Current practices may need to be reconsidered to exploit the full societal benefit of VAMs, including more efficient policies to guarantee market exclusivity for incremental innovation, acknowledgment of a fair price premium based on a specific value framework and the acceptance of low-cost evidence generation methods. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|